Dr. Michael D. Marsh, M.D.
Internal Medicine (Internal Medicine Physician)
4418 Vineland Ave Ste 102
Toluca Lake, CA 91602
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 699
Licensed in California since 1982, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A39430 (first issued 1982; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Saint Joseph Medical Ctr Burbank, CA
Medical groups
- Premiere Medical Center of Burbank, Inc (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 699
- Services billed
- 20,218
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 8,720 | 110 |
| Professional service for preparation and provision of 1 or more antigens | 4,600 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,668 | 405 |
| Insertion of needle into vein for collection of blood sample | 1,020 | 497 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 932 | 489 |
| Thyroid hormone, t3 measurement, free | 887 | 474 |
| Blood test, basic group of blood chemicals (calcium, total) | 851 | 425 |
| Liver function blood test panel | 843 | 424 |
| Blood test, thyroid stimulating hormone (tsh) | 832 | 458 |
| Thyroxine (thyroid chemical), free | 824 | 453 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 38 payments worth $796 in total to this clinician.
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107 |
|---|---|
| Gilead Sciences, Inc. | $87.31 |
| GlaxoSmithKline, LLC. | $75.74 |
| Bayer HealthCare Pharmaceuticals Inc. | $69.09 |
| Lundbeck LLC | $60.06 |
| Optinose US, Inc. | $53.18 |
| Indivior Inc. | $47.29 |
| AstraZeneca Pharmaceuticals LP | $37.90 |
| Food and Beverage | $796 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $503,478 in research payments for these studies, mostly to the institutions running them.
- ANCHOR
AstraZeneca Pharmaceuticals LP - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Roche Cancer Screening Collection Study
Genentech, Inc. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc. - A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
AstraZeneca Pharmaceuticals LP - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.